Cargando…

Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

Detalles Bibliográficos
Autores principales:	Zeyen, Thomas, Paech, Daniel, Weller, Johannes, Schäfer, Niklas, Tzaridis, Theophilos, Duffy, Cathrina, Nitsch, Louisa, Schneider, Matthias, Potthoff, Anna-Laura, Steinbach, Joachim Peter, Hau, Peter, Schlegel, Uwe, Seidel, Clemens, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Zeiner, Pia Susan, Tabatabai, Ghazaleh, Galldiks, Norbert, Stummer, Walter, Hattingen, Elke, Glas, Martin, Radbruch, Alexander, Herrlinger, Ulrich, Schaub, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689511/ https://www.ncbi.nlm.nih.gov/pubmed/37921974 http://dx.doi.org/10.1007/s11060-023-04488-z

Ejemplares similares

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
por: Zeyen, Thomas, et al.
Publicado: (2023)

Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
por: Weller, Johannes, et al.
Publicado: (2022)

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
por: Weller, J., et al.
Publicado: (2023)

Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
por: Zeyen, Thomas, et al.
Publicado: (2022)

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
por: Weller, Johannes, et al.
Publicado: (2023)

A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma
por: Kebir, Sied, et al.
Publicado: (2020)

Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
por: Tremont-Lukats, Ivo W., et al.
Publicado: (2019)

Quantitative T1‐mapping detects cloudy‐enhancing tumor compartments predicting outcome of patients with glioblastoma
por: Müller, Andreas, et al.
Publicado: (2016)

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma
por: Kebir, Sied, et al.
Publicado: (2016)

Distress in Neuro-Oncology Patients and Its Implications for Communication
por: Roos, Carolin, et al.
Publicado: (2023)

NOAS
por: Mulder, Henk
Publicado: (1997)

NOAS
por: Mulder, Henk
Publicado: (1997)

NOAS
por: Mulder, H
Publicado: (1997)

NOAS
por: Mulder, H
Publicado: (1996)

Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
por: Das, Sunit, et al.
Publicado: (2020)

Reduction of microbleeds by immunosuppression in a patient with Aβ-related vascular inflammation
por: Traschütz, Andreas, et al.
Publicado: (2015)

NOAS -02 Minutes
por: Bouthéon, M
Publicado: (1990)

NOAS Minutes - 05
Publicado: (1989)

NOAS - 01 minutes
por: Elena, M, et al.
Publicado: (1989)

Noa visiting the CCC
por: Traczyk, Piotr
Publicado: (2022)

Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature
por: Tzaridis, Theophilos, et al.
Publicado: (2020)

Auxin influx inhibitors 1-NOA, 2-NOA, and CHPAA interfere with membrane dynamics in tobacco cells
por: Laňková, Martina, et al.
Publicado: (2010)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
por: Urban, Hans, et al.
Publicado: (2022)

Noa visits the ATLAS Visitor Centre
por: Anthony, Katarina
Publicado: (2022)

The Challenges and Hopes in Treating Patients with NOA
por: Friedler, Shevach
Publicado: (2023)

Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study
por: Dirven, Linda, et al.
Publicado: (2020)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

NOAS: Minutes of meeting on 24 April 1996
por: Mulder, H
Publicado: (1996)

NOAS: minutes of meeting on 7/11/96
Publicado: (1996)

Survival after resection of brain metastasis: impact of synchronous versus metachronous metastatic disease
por: Potthoff, Anna-Laura, et al.
Publicado: (2023)

Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression
por: Kondo, Masaaki, et al.
Publicado: (2017)

NOA61-Polymer Fiber Fizeau Interferometer with a Flexible NOA65-Polymer Taper for Simultaneous Measurement of Tilt Angle and Temperature
por: Lee, Cheng-Ling, et al.
Publicado: (2021)

Pseudoprogression prediction in high grade primary CNS tumors by use of radiomics
por: Ari, Asena Petek, et al.
Publicado: (2022)

Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps
por: Reimer, Caroline, et al.
Publicado: (2017)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

Reunion NOAS 06 le 22 novembre 1989
por: B, Marcel
Publicado: (1989)

NOA: a novel Network Ontology Analysis method
por: Wang, Jiguang, et al.
Publicado: (2011)

Réunion NOAS 8 du 11 Avril 1990
por: Boillot, J, et al.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_ij3dctmfqnn69v86ndh056fiop